Company / Accounts Receivable
C4 Therapeutics, Inc. Accounts Receivable History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$2.4M
FY2025
5-year range
$1.5M / $11.8M
FY2022-FY2025
Trend
-22.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $12M to $2M over the past 2 years.
Based on SEC 10-K filings.
$2M in FY2025 with a 3-year CAGR of +17.7%.
Declined from $12M to $2M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +17.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +17.7%, indicating consistent growth.
- In FY2025, accounts receivable decreased 22.6% year-over-year.
Company context
Key Data Points
- Altman Z-Score -1.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.4M | -22.6% |
| FY2024 | $3.1M | -73.7% |
| FY2023 | $11.8M | +701.0% |
| FY2022 | $1.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026